Novy Jicin

• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER … Ended recruitment
  2023-503995-26-00 5 2021-05-11 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended recruitment
  2023-505246-26-00 5 2016-01-27 High- or very-high risk, localized or locally advanced prostate cancer
• A Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants with mHSPC Ended recruitment
  2023-508607-20-00 5 2015-11-27 Metastatic Hormone-sensitive Prostate Cancer
• A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate- … Ended
  2024-512497-10-00 5 2025-09-16 Moderate to Severe Plaque Psoriasis
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop … Ended
  2023-506558-20-00 5 2024-06-26 Dermatitis atopic
• An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budig … Ended
  2023-508356-19-00 4 2024-06-25 Pancreatic adenocarcinoma metastatic
• A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap … Ended
  2022-502653-34-01 11 2024-05-30 Atopic dermatitis and moderate-to severe atopic hand eczema
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject … Ended
  2023-505842-24-00 5 2024-05-07 Moderate to Severe Plaque Psoriasis
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight … Ended
  2023-509668-11-00 6 2022-06-15 Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
• Study of efficacy, safety and tolerability of DFV890 in patients with knee osteoarthritis Ended
  2023-507559-30-00 4 2021-11-09 Knee Osteoarthritis
• An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev … Ended
  2022-502361-15-00 5 2019-12-12 Moderate-to-Severe Plaque Psoriasis
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS) Ended
  2023-503898-38-00 5 2019-05-24 Atopic Dermatitis
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3 … Ended
  2022-501251-81-00 5 2017-06-08 Renal cell carcinoma
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
• A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall … Ended
  2024-512477-27-00 4 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar

Showing 49–69 of 69 trials